Aditxt Management
Management criteria checks 3/4
Aditxt's CEO is Amro Albanna, appointed in Jan 2017, has a tenure of 7.42 years. total yearly compensation is $519.23K, comprised of 83.2% salary and 16.8% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth $519.22. The average tenure of the management team and the board of directors is 3.4 years and 5.5 years respectively.
Key information
Amro Albanna
Chief executive officer
US$519.2k
Total compensation
CEO salary percentage | 83.2% |
CEO tenure | 7.4yrs |
CEO ownership | 0.02% |
Management average tenure | 3.4yrs |
Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Aditxt gains on regaining compliance with Nasdaq listing requirements
Sep 29Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split
Sep 13Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate
Jul 08Aditxt adds Lauren Chung to board of directors
Jun 18Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring
Dec 14We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth
Nov 23CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$41m |
Dec 31 2023 | US$519k | US$432k | -US$33m |
Sep 30 2023 | n/a | n/a | -US$30m |
Jun 30 2023 | n/a | n/a | -US$27m |
Mar 31 2023 | n/a | n/a | -US$28m |
Dec 31 2022 | US$500k | US$500k | -US$28m |
Sep 30 2022 | n/a | n/a | -US$43m |
Jun 30 2022 | n/a | n/a | -US$46m |
Mar 31 2022 | n/a | n/a | -US$46m |
Dec 31 2021 | US$2m | US$280k | -US$46m |
Sep 30 2021 | n/a | n/a | -US$27m |
Jun 30 2021 | n/a | n/a | -US$20m |
Mar 31 2021 | n/a | n/a | -US$14m |
Dec 31 2020 | US$252k | US$252k | -US$9m |
Sep 30 2020 | n/a | n/a | -US$5m |
Jun 30 2020 | n/a | n/a | -US$4m |
Mar 31 2020 | n/a | n/a | -US$6m |
Dec 31 2019 | US$2m | US$252k | -US$6m |
Sep 30 2019 | n/a | n/a | -US$5m |
Jun 30 2019 | n/a | n/a | -US$6m |
Mar 31 2019 | n/a | n/a | -US$5m |
Dec 31 2018 | US$180k | US$180k | -US$6m |
Dec 31 2017 | US$198k | US$51k | -US$852k |
Compensation vs Market: Amro's total compensation ($USD519.23K) is about average for companies of similar size in the US market ($USD676.60K).
Compensation vs Earnings: Amro's compensation has increased whilst the company is unprofitable.
CEO
Amro Albanna (54 yo)
7.4yrs
Tenure
US$519,233
Compensation
Mr. Amro A. Albanna has been Chief Executive Officer and a Director of Aditxt, Inc. (formerly known as ADiTx Therapeutics, Inc.) since 2017 and serves as its Chairman of the Board and served as its Preside...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 7.4yrs | US$519.23k | 0.019% $ 519.2 | |
Co-Founder | 7.4yrs | US$358.84k | 0.38% $ 10.5k | |
Chief Financial Officer | 2.8yrs | US$381.45k | 0.0040% $ 109.5 | |
Chief Commercialization Officer | 2.2yrs | US$390.33k | 0.0043% $ 117.7 | |
Chief Operating Officer | 3.9yrs | no data | 0.0043% $ 117.7 | |
Director of Human Resources | 3.4yrs | no data | no data | |
Senior Vice President of Clinical Development – Transplantation | 3.4yrs | no data | no data | |
Senior Vice President of Preclinical Research & Discovery | 2.4yrs | no data | no data |
3.4yrs
Average Tenure
58yo
Average Age
Experienced Management: ADTX's management team is considered experienced (3.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 7.4yrs | US$519.23k | 0.019% $ 519.2 | |
Co-Founder | 7.4yrs | US$358.84k | 0.38% $ 10.5k | |
Independent Director | 3.9yrs | US$15.00k | 0.00030% $ 8.2 | |
Independent Director | less than a year | no data | 0.013% $ 357.5 | |
Independent Director | 5.5yrs | US$15.00k | 0.00065% $ 17.8 |
5.5yrs
Average Tenure
61yo
Average Age
Experienced Board: ADTX's board of directors are considered experienced (5.5 years average tenure).